• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D filed by Rhythm Pharmaceuticals Inc.

    3/20/24 5:51:56 PM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RYTM alert in real time by email
    SC 13D 1 d813811dsc13d.htm SC 13D SC 13D

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment ___)*

     

     

    Rhythm Pharmaceuticals, Inc.

    (Name of Issuer)

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

    76243J105

    (CUSIP Number)

    Alexander Rakitin

    Perceptive Advisors LLC

    51 Astor Place, 10th Floor

    New York, NY 10003

    (646) 205-5340

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    March 13, 2024

    (Date of Event Which Requires Filing of this Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☒

     

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Section 240.13d-7 for other parties to whom copies are to be sent.

     

     

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 76243J105

     

     1.    

     Names of Reporting Persons.

     

     Perceptive Advisors LLC

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC Use Only

     

     4.  

     Source of Funds (See Instructions)

     

     AF

     5.  

     Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

     ☐

     6.  

     Citizenship or Place of Organization

     

     Delaware

    Number of

    Shares  Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

     

        7.    

     Sole Voting Power

     

     0

        8.  

     Shared Voting Power

     

     3,268,579

        9.  

     Sole Dispositive Power

     

     0

       10.  

     Shared Dispositive Power

     

     3,268,579

    11.    

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     3,268,579

    12.  

     Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

     ☐

    13.  

     Percent of Class Represented by Amount in Row (11)

     

     5.4%

    14.  

     Type of Reporting Person (See Instructions)

     

     OO

     


    CUSIP No. 76243J105

     

     1.    

     Names of Reporting Persons.

     

     Perceptive Life Sciences Master Fund, Ltd.

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC Use Only

     

     4.  

     Source of Funds (See Instructions)

     

     WC

     5.  

     Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

     ☐

     6.  

     Citizenship or Place of Organization

     

     Cayman Islands

    Number of

    Shares  Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

     

        7.    

     Sole Voting Power

     

     0

        8.  

     Shared Voting Power

     

     3,268,579

        9.  

     Sole Dispositive Power

     

     0

       10.  

     Shared Dispositive Power

     

     3,268,579

    11.    

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     3,268,579

    12.  

     Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

     ☐

    13.  

     Percent of Class Represented by Amount in Row (11)

     

     5.4%

    14.  

     Type of Reporting Person (See Instructions)

     

     CO

     


    CUSIP No. 76243J105

     

     1.    

     Names of Reporting Persons.

     

     Joseph Edelman

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC Use Only

     

     4.  

     Source of Funds (See Instructions)

     

     AF

     5.  

     Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

     ☐

     6.  

     Citizenship or Place of Organization

     

     United States of America

    Number of

    Shares  Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

     

        7.    

     Sole Voting Power

     

     0

        8.  

     Shared Voting Power

     

     3,268,579

        9.  

     Sole Dispositive Power

     

     0

       10.  

     Shared Dispositive Power

     

     3,268,579

    11.    

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     3,268,579

    12.  

     Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

     ☐

    13.  

     Percent of Class Represented by Amount in Row (11)

     

     5.4%

    14.  

     Type of Reporting Person (See Instructions)

     

     IN

     


    CUSIP No. 76243J105

     

    Item 1.

    Security and Issuer

    This Schedule 13D relates to the Common Stock, par value $0.001 per share (the “Common Stock”) of Rhythm Pharmaceuticals, Inc. (the “Issuer”), which has its principal executive offices at 222 Berkeley Street, 12th Floor, Boston, Massachusetts 02116.

     

    Item 2.

    Identity and Background

     

      (a)

    This Schedule 13D is being filed by Perceptive Advisors LLC (“Perceptive Advisors” or “Perceptive”), Joseph Edelman (“Mr. Edelman”) and Perceptive Life Sciences Master Fund, Ltd. (the “Master Fund”, and together with Perceptive Advisors and Mr. Edelman, each of the foregoing, a “Reporting Person,” and collectively, the “Reporting Persons”). Perceptive Advisors serves as the investment advisor to the Master Fund and Mr. Edelman is the managing member of Perceptive Advisors. The agreement among the Reporting Persons to file this Schedule 13D jointly in accordance with Rule 13d-1(k) of the Securities Exchange Act of 1934, as amended, is attached hereto as Exhibit 1.

     

      (b)

    The address of the principal business office of each of the Reporting Persons is 51 Astor Place 10th Floor, New York, NY 10003.

     

      (c)

    The principal business of Perceptive Advisors is managing funds in connection with purchasing, holding and selling securities for investment purposes. The principal business of the Master Fund is to invest in securities. The principal occupation of Mr. Edelman is as the managing member of Perceptive Advisors and other related entities.

     

      (d)

    During the last five years, none of the Reporting Persons, nor to the Reporting Persons’ knowledge, any of the persons listed on Schedule A to this Schedule 13D, has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

     

      (e)

    During the last five years, none of the Reporting Persons, nor to the Reporting Persons’ knowledge, any of the persons listed on Schedule A to this Schedule 13D, has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree of final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

     

      (f)

    Perceptive Advisors is a Delaware limited liability company. Mr. Edelman is a United States citizen. The Master Fund is a Cayman Islands corporation.

    Schedule A to this Schedule 13D sets forth the information regarding the directors of the Master Fund.

     

    Item 3.

    Source and Amount of Funds or Other Consideration

    The source of funds for the acquisitions of the Common Stock reported on this Schedule 13D was working capital of the Master Fund.

     

    Item 4.

    Purpose of Transaction

    The Reporting Persons acquired the Common Stock set forth in this Schedule 13D and hold their shares of Common Stock for investment purposes.

    Each Reporting Person expects to continuously review such person’s investment in the Issuer and, depending on various factors including but not limited to, the price of the shares of Common Stock, the terms and conditions of the transaction, prevailing market conditions and such other considerations as such Reporting Person deems relevant, may at any time or from time to time, and subject to any required regulatory approvals, acquire additional shares of Common Stock, preferred stock or other securities convertible into or exercisable or exchangeable for Common Stock from time to time on the open market, in privately- negotiated transactions, directly from the Issuer, or upon the exercise or conversion of securities convertible into or exercisable or exchangeable for Common Stock.


    Each Reporting Person also may, at any time, subject to compliance with applicable securities laws and regulatory requirements dispose of or distribute some or all of its Common Stock or such other securities as it owns or may subsequently acquire depending on various factors, including but not limited to, the price of the shares, the terms and conditions of the transaction and prevailing market conditions, as well as the liquidity and diversification objectives.

    Consistent with their investment intent, each Reporting Person may from time to time discuss with the Issuer’s management, directors, other shareholders and others, the Issuer’s performance, business, strategic direction, capital structure, product development program, prospects and management, as well as various ways of maximizing stockholder value, which may or may not include extraordinary transactions.

    Representatives of the Reporting Persons have discussed with the Issuer potential financing options, possibly involving additional investment by the Reporting Persons and other investors, and potential governance rights of investors participating in such financing arrangements. There is no certainty that these discussions will continue, or that any specific plan will develop or materialize, or if one does, its timing. Except as indicated herein, no Reporting Person, as a stockholder of the Issuer, has any plans or proposals that relates or would result in any of the transactions or other matters specified in clauses (a) through (j) of Item 4 of Schedule 13D. Each Reporting Person may, at any time and from time to time, review or reconsider its or his position and/or change its or his purpose and/or formulate plans or proposals with respect thereto.

     

    Item 5.

    Interest in Securities of the Issuer

     

      (a)

    The information set forth in rows 11 and 13 of the cover pages to this Schedule 13D is incorporated by reference. The percentage set forth in row 13 is based on 60,140,495 shares of Common Stock outstanding as of February 23, 2024, as reported by the Issuer in its Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 29, 2024.

     

      (b)

    The information set forth in rows 7 through 10 of the cover pages to this Schedule 13D is incorporated by reference.

     

      (c)

    Schedule B to this Schedule 13D sets forth the transactions in the Common Stock of the Issuer effected by the Reporting Persons during the past sixty days, and is incorporated by reference into this Item 5(c).

     

      (d)

    No person other than the Reporting Persons disclosed in this Schedule 13D is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Common Shares subject to this Schedule 13D.

     

      (e)

    Not applicable.

     

    Item 6.

    Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer

    The information set forth in Item 4 above is incorporated by reference to this Item 6.

     

    Item 7.

    Material to be Filed as Exhibits

    Exhibit 1   Joint Filing Agreement.


    SIGNATURES

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: March 20, 2024

     

    PERCEPTIVE ADVISORS LLC
    By:  

    /s/ Joseph Edelman

      Name: Joseph Edelman
      Title: Managing Member

    /s/ Joseph Edelman

    JOSEPH EDELMAN
    PERCEPTIVE LIFE SCIENCES MASTER FUND, LTD.
    By:  

    /s/ Joseph Edelman

      Name: Joseph Edelman
      Title: Managing Member


    Schedule A

    The following sets forth the name, address, principal occupation, citizenship and beneficial ownership of the shares of Common Stock (to the extent not pursuant to Item 5(a)) of each director of the Master Fund (to the extent not set forth in Item 2).

     

    Master Fund

    Name and Citizenship

      

    Position

      

    Principal Business Address

      

    Beneficial Ownership of

    Shares of Common Stock

    Scott Dakers

    (United Kingdom)

       Director   

    c/o Elian Fiduciary Services (Cayman) Limited

    190 Elgin Avenue, George Town

    Grand Cayman KY1-9007

    Cayman Islands

       None

    Ernest A. Morrison

    (United Kingdom)

       Director   

    Cox Hallett Wilkinson

    Milner House

    18 Parliament Street

    P.O. Box HM 1561

    Hamilton HM FX

    Bermuda

       None

    James Nicholas

    (United States)

       Director   

    c/o GenesisPoint LLC

    30 Old Kings Highway S

    Darien, CT 06820

       None


    Schedule B

     

    Name

       Date of Transaction    Number of Securities
    Acquired or Disposed
        

    Type of Transaction

       Price per Security  

    Master Fund

       01/12/2024      1,000      Sale of Call Options    $ 1.95  

    Master Fund

       01/12/2024      2,808      Purchase of Common Stock    $ 43.03(1)(2)  

    Master Fund

       01/19/2024      43,576      Purchase of Common Stock    $ 40.61(1)(3)  

    Master Fund

       01/19/2024      21,424      Purchase of Common Stock    $ 41.022(1)(4)  

    Master Fund

       01/22/2024      23,429      Purchase of Common Stock    $ 41.50(1)(5)  

    Master Fund

       01/22/2024      6,830      Purchase of Common Stock    $ 42.42(1)(6)  

    Master Fund

       01/23/2024      14,158      Purchase of Common Stock    $ 41.43(1)(7)  

    Master Fund

       01/23/2024      7,870      Purchase of Common Stock    $ 42.34(1)(8)  

    Master Fund

       01/24/2024      14,368      Purchase of Common Stock    $ 42.32(1)(9)  

    Master Fund

       01/24/2024      17,881      Purchase of Common Stock    $ 43.46(1)(10)  

    Master Fund

       01/24/2024      24,758      Purchase of Common Stock    $ 44.19(1)(11)  

    Master Fund

       01/24/2024      4,900      Purchase of Common Stock    $ 45.41(1)(12)  

    Master Fund

       01/24/2024      59,258      Purchase of Common Stock    $ 46.62(1)(13)  

    Master Fund

       01/24/2024      40,496      Purchase of Common Stock    $ 47.38(1)(14)  

    Master Fund

       01/25/2024      29,221      Purchase of Common Stock    $ 44.70 (1)(15)  

    Master Fund

       01/25/2024      18,746      Purchase of Common Stock    $ 45.40 (1)(16)  

    Master Fund

       01/25/2024      2,033      Purchase of Common Stock    $ 46.16 (1)(17)  

    Master Fund

       01/26/2024      14,404      Purchase of Common Stock    $ 44.06 (1)(18)  

    Master Fund

       01/26/2024      35,596      Purchase of Common Stock    $ 45.165 (1)(19)  

    Master Fund

       01/29/2024      46,480      Purchase of Common Stock    $ 44.58 (1)(20)  

    Master Fund

       01/29/2024      22,992      Purchase of Common Stock    $ 45.20 (1)(21)  

    Master Fund

       01/30/2024      14,507      Purchase of Common Stock    $ 44.44 (1)(22)  

    Master Fund

       01/30/2024      13,953      Purchase of Common Stock    $ 45.49 (1)(23)  

    Master Fund

       01/31/2024      14,561      Purchase of Common Stock    $ 44.51 (1)(24)  

    Master Fund

       01/31/2024      14,575      Purchase of Common Stock    $ 44.61 (1)(25)  

    Master Fund

       01/31/2024      7,123      Purchase of Common Stock    $ 46.80 (1)(26)  

    Master Fund

       02/01/2024      10,983      Purchase of Common Stock    $ 44.89 (1)(27)  

    Master Fund

       02/01/2024      12,502      Purchase of Common Stock    $ 45.24 (1)(28)  

    Master Fund

       02/01/2024      26,515      Purchase of Common Stock    $ 46.22 (1)(29)  

    Master Fund

       02/02/2024      48,483      Purchase of Common Stock    $ 44.97 (1)(30)  

    Master Fund

       02/02/2024      1,517      Purchase of Common Stock    $ 45.51 (1)(31)  

    Master Fund

       02/05/2024      13,686      Purchase of Common Stock    $ 43.91 (1)(32)  

    Master Fund

       02/05/2024      5,763      Purchase of Common Stock    $ 44.86 (1)(33)  

    Master Fund

       02/05/2024      29,672      Purchase of Common Stock    $ 45.90 (1)(34)  

    Master Fund

       02/06/2024      11,767      Purchase of Common Stock    $ 46.18 (1)(35)  

    Master Fund

       02/06/2024      35,543      Purchase of Common Stock    $ 47.14 (1)(36)  

    Master Fund

       02/06/2024      27,190      Purchase of Common Stock    $ 48.01 (1)(37)  

    Master Fund

       02/06/2024      500      Purchase of Common Stock    $ 48.73 (1)(38)  

    Master Fund

       02/07/2024      4,454      Purchase of Common Stock    $ 46.03 (1)(39)  

    Master Fund

       02/07/2024      9,362      Purchase of Common Stock    $ 47.40 (1)(40)  

    Master Fund

       02/07/2024      25,922      Purchase of Common Stock    $ 47.98 (1)(41)  

    Master Fund

       02/08/2024      4,500      Purchase of Common Stock    $ 47.37 (1)(42)  

    Master Fund

       02/08/2024      11,465      Purchase of Common Stock    $ 47.97 (1)(43)  

    Master Fund

       02/08/2024      100      Purchase of Common Stock    $ 48.54  

    Master Fund

       02/09/2024      400      Purchase of Common Stock    $ 48.17 (1)(44)  

    Master Fund

       02/09//2024      12,581      Purchase of Common Stock    $ 49.79 (1)(45)  

    Master Fund

       02/09/2024      14,541      Purchase of Common Stock    $ 50.59 (1)(46)  

    Master Fund

       02/09/2024      5,597      Purchase of Common Stock    $ 51.36 (1)(47)  

    Master Fund

       02/15/2024      6,213      Purchase of Common Stock    $ 50.17 (1)(48)  

    Master Fund

       02/15/2024      2,353      Purchase of Common Stock    $ 50.55 (1)(49)  

     

    (1)

    The price reported is a weighted average price. The Reporting Persons undertake to provide to the staff of the Securities and Exchange Commission, upon request, full information regarding the shares of Common Stock sold at each separate price within the ranges of the prices reported.

    (2)

    These shares were purchased in multiple transactions at prices ranging from $42.68 to $43.57, inclusive.

    (3)

    These shares were purchased in multiple transactions at prices ranging from $39:95 to $40.94, inclusive.


    (4)

    These shares were purchased in multiple transactions at prices ranging from $40.98 to $41.96, inclusive.

    (5)

    These shares were purchased in multiple transactions at prices ranging from $40.95 to $41.195, inclusive.

    (6)

    These shares were purchased in multiple transactions at prices ranging from $41.985 to $42.84, inclusive.

    (7)

    These shares were purchased in multiple transactions at prices ranging from $40.91 to $41.89, inclusive.

    (8)

    These shares were purchased in multiple transactions at prices ranging from $41.91 to $42.88, inclusive.

    (9)

    These shares were purchased in multiple transactions at prices ranging from $41.81 to $42.805, inclusive.

    (10)

    These shares were purchased in multiple transactions at prices ranging from $42.81 to $43.80, inclusive.

    (11)

    These shares were purchased in multiple transactions at prices ranging from $43.81 to $44.68, inclusive.

    (12)

    These shares were purchased in multiple transactions at prices ranging from $44.94 to $45.91, inclusive.

    (13)

    These shares were purchased in multiple transactions at prices ranging from $46.06 to $47.05, inclusive.

    (14)

    These shares were purchased in multiple transactions at prices ranging from $47.06 to $47.925, inclusive.

    (15)

    These shares were purchased in multiple transactions at prices ranging from $44.05 to $45.045, inclusive.

    (16)

    These shares were purchased in multiple transactions at prices ranging from $45.05 to $46.00, inclusive.

    (17)

    These shares were purchased in multiple transactions at prices ranging from $46.055 to $46.35, inclusive.

    (18)

    These shares were purchased in multiple transactions at prices ranging from $43.315 to $44.31, inclusive.

    (19)

    These shares were purchased in multiple transactions at prices ranging from $44.315 to $45.165, inclusive.

    (20)

    These shares were purchased in multiple transactions at prices ranging from $43.885 to $44.88, inclusive.

    (21)

    These shares were purchased in multiple transactions at prices ranging from $44.885 to $45.64, inclusive.

    (22)

    These shares were purchased in multiple transactions at prices ranging from $43.96 to $44.95, inclusive.

    (23)

    These shares were purchased in multiple transactions at prices ranging from $45.01 to $45.78, inclusive.

    (24)

    These shares were purchased in multiple transactions at prices ranging from $44.11 to $45.10, inclusive.

    (25)

    These shares were purchased in multiple transactions at prices ranging from $45.12 to $45.61, inclusive.

    (26)

    These shares were purchased in multiple transactions at prices ranging from $46.135 to $46.98, inclusive.

    (27)

    These shares were purchased in multiple transactions at prices ranging from $43.90 to $44.89, inclusive.

    (28)

    These shares were purchased in multiple transactions at prices ranging from $44.90 to $45.85, inclusive.

    (29)

    These shares were purchased in multiple transactions at prices ranging from $45.93 to $46.70, inclusive.

    (30)

    These shares were purchased in multiple transactions at prices ranging from $44.415 to $45.405, inclusive.

    (31)

    These shares were purchased in multiple transactions at prices ranging from $45.42 to $45.65, inclusive.

    (32)

    These shares were purchased in multiple transactions at prices ranging from $43.52 to $44.505, inclusive.

    (33)

    These shares were purchased in multiple transactions at prices ranging from $44.52 to $45.41, inclusive.

    (34)

    These shares were purchased in multiple transactions at prices ranging from $45.42 to $46.21, inclusive.

    (35)

    These shares were purchased in multiple transactions at prices ranging from $45.58 to $46.57, inclusive.

    (36)

    These shares were purchased in multiple transactions at prices ranging from $46.58 to $47.57, inclusive.

    (37)

    These shares were purchased in multiple transactions at prices ranging from $47.58 to $48.525, inclusive.

    (38)

    These shares were purchased in multiple transactions at prices ranging from $48.63 to $48.96, inclusive.

    (39)

    These shares were purchased in multiple transactions at prices ranging from $45.46 to $46.43, inclusive.

    (40)

    These shares were purchased in multiple transactions at prices ranging from $46.75 to $47.71, inclusive.

    (41)

    These shares were purchased in multiple transactions at prices ranging from $47.76 to $48.49, inclusive.

    (42)

    These shares were purchased in multiple transactions at prices ranging from $46.565 to $47.555, inclusive.

    (43)

    These shares were purchased in multiple transactions at prices ranging from $47.565 to $48.52, inclusive.

    (44)

    These shares were purchased in multiple transactions at prices ranging from $47.81 to $48.29, inclusive.

    (45)

    These shares were purchased in multiple transactions at prices ranging from $49.175 to $50.17, inclusive.

    (46)

    These shares were purchased in multiple transactions at prices ranging from $50.175 to $51.17, inclusive.

    (47)

    These shares were purchased in multiple transactions at prices ranging from $51.175 to $51.64, inclusive.

    (48)

    These shares were purchased in multiple transactions at prices ranging from $49.465 to $50.45, inclusive.

    (49)

    These shares were purchased in multiple transactions at prices ranging from $50.47 to $50.735, inclusive.

     

    Get the next $RYTM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RYTM

    DatePrice TargetRatingAnalyst
    4/7/2025$63.00Neutral → Buy
    BofA Securities
    3/5/2025$78.00Buy
    Stifel
    1/2/2025$80.00Buy
    Jefferies
    12/20/2024$76.00Outperform
    Oppenheimer
    10/21/2024$70.00Buy
    Guggenheim
    9/18/2024$64.00Buy
    H.C. Wainwright
    9/17/2024$64.00Mkt Outperform
    JMP Securities
    5/8/2024$49.00 → $42.00Buy → Neutral
    BofA Securities
    More analyst ratings

    $RYTM
    Financials

    Live finance-specific insights

    See more
    • Rhythm Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Update

      -- First quarter 2025 net product revenue from global sales of IMCIVREE® (setmelanotide) of $37.7 million -- -- Setmelanotide pivotal Phase 3 TRANSCEND trial met primary endpoint with -19.8% placebo-adjusted BMI reduction in patients (N=120) with acquired hypothalamic obesity -- -- U.S. and EU regulatory submissions for setmelanotide in acquired hypothalamic obesity on track to be completed in the third quarter of 2025 -- -- Topline data from Phase 2 trial of oral MC4R agonist bivamelagon on track to be announced in third quarter of 2025 -- -- Cash on-hand expected to support planned operations into 2027 -- -- Management to host conference call today at 8:00 a.m. ET -- B

      5/7/25 7:00:00 AM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rhythm Pharmaceuticals to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025

      BOSTON, April 23, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Wednesday, May 7, 2025 to report its first quarter 2025 financial results and provide a corporate update. To access the live conference call, participants may register here. While not required, it is recommended that participants join the call ten minutes prior to the scheduled start. A webcast of the call will also be available under "Events and Presentations" in the Invest

      4/23/25 8:00:00 AM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rhythm Pharmaceuticals Announces Pivotal Phase 3 TRANSCEND Trial Meets Primary Endpoint with -19.8% Placebo-adjusted BMI Reduction in Patients (N=120) with Acquired Hypothalamic Obesity

      -- Patients with acquired hypothalamic obesity on setmelanotide therapy (n=81) achieved mean BMI change of -16.5% compared with +3.3% for placebo (n=39) at 52 weeks (p<0.0001) -- -- -19.2% placebo-adjusted BMI reduction achieved in adult patients 18 years old and older (n=49) at 52 weeks -- -- -20.2% placebo-adjusted BMI reduction achieved in patients younger than 18 years old (n=71) at 52 weeks -- -- Regulatory submissions in the U.S. and EU anticipated to be completed in the third quarter of 2025 -- -- Company to host conference call today at 8 a.m. ET -- BOSTON, April 07, 2025 (GLOBE NEWSWIRE) --  Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage bi

      4/7/25 7:00:00 AM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RYTM
    Leadership Updates

    Live Leadership Updates

    See more
    • Rhythm Pharmaceuticals Announces Appointment of Alastair Garfield, Ph.D., as Chief Scientific Officer

      BOSTON, July 08, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced the appointment of Alastair "Al" Garfield, Ph.D. as Chief Scientific Officer, effective July 1. "We are excited to welcome Al back to Rhythm as we continue to leverage our understanding of the melanocortin-4 receptor (MC4R) pathway to bring potential therapies to patients and their families," said David Meeker, M.D., Rhythm Chairman, Chief Executive Officer and President. "Al's leadership and established scientific expertise and experience

      7/8/24 8:00:00 AM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rhythm Pharmaceuticals Appoints Dana Washburn, M.D., as Senior Vice President of Clinical Development

      BOSTON, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases, today announced the appointment of Dana Washburn, M.D., as Senior Vice President of Clinical Development and as a member of the Company's Executive Leadership Team, effective September 26, 2022. As SVP of Clinical Development, Dr. Washburn will lead the Company's robust clinical development program, clinical operations, and data management. "Dr. Washburn is a collaborative, resourceful leade

      10/6/22 4:02:00 PM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wren Appoints Bart Henderson as Chief Executive Officer

      Wren Therapeutics, a biopharmaceutical company transforming drug discovery for neurodegenerative diseases, today announced the appointment of Bart Henderson as Chief Executive Officer. Wren's unique drug discovery platform harnesses advances in the biophysics of protein assembly dynamics to target the toxic fleeting protein intermediates, the oligomers, in neurodegenerative disease pathways, and discover small molecules that can block their generation with precision. Bart brings broad leadership experience in the biotechnology industry as a founder and co-founder of several companies including Torque (now Repertoire Immune Medicines), Rhythm (NASDAQ:RYTM) and its subsidiary Motus (acquired

      3/4/22 8:00:00 AM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RYTM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Rhythm Pharmaceuticals upgraded by BofA Securities with a new price target

      BofA Securities upgraded Rhythm Pharmaceuticals from Neutral to Buy and set a new price target of $63.00

      4/7/25 12:20:34 PM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stifel resumed coverage on Rhythm Pharmaceuticals with a new price target

      Stifel resumed coverage of Rhythm Pharmaceuticals with a rating of Buy and set a new price target of $78.00

      3/5/25 7:44:16 AM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies initiated coverage on Rhythm Pharmaceuticals with a new price target

      Jefferies initiated coverage of Rhythm Pharmaceuticals with a rating of Buy and set a new price target of $80.00

      1/2/25 8:06:46 AM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RYTM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $RYTM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Chief Human Resources Officer Cramer Pamela J. sold $457,663 worth of shares (7,031 units at $65.09) and exercised 7,031 shares at a strike of $6.80 (SEC Form 4)

      4 - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Issuer)

      5/1/25 4:53:44 PM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP, Head of International Mazabraud Yann sold $438,946 worth of shares (6,745 units at $65.08), decreasing direct ownership by 15% to 37,655 units (SEC Form 4)

      4 - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Issuer)

      5/1/25 4:52:53 PM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP, Head of International Mazabraud Yann converted options into 21,780 shares, increasing direct ownership by 96% to 44,400 units (SEC Form 4)

      4 - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Issuer)

      4/16/25 4:30:22 PM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Rhythm Pharmaceuticals Inc.

      SC 13G - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Subject)

      11/14/24 9:50:26 PM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Rhythm Pharmaceuticals Inc.

      SC 13G/A - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Subject)

      11/14/24 5:46:11 PM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Rhythm Pharmaceuticals Inc.

      SC 13G/A - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Subject)

      11/12/24 5:23:38 PM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RYTM
    SEC Filings

    See more
    • SEC Form 144 filed by Rhythm Pharmaceuticals Inc.

      144 - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Subject)

      5/30/25 4:35:58 PM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Rhythm Pharmaceuticals Inc.

      SCHEDULE 13G/A - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Subject)

      5/15/25 6:20:49 PM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Rhythm Pharmaceuticals Inc.

      SCHEDULE 13G/A - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Subject)

      5/15/25 4:19:29 PM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RYTM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Rhythm Pharmaceuticals Announces New Data Presentations on Patients with Acquired or Congenital Hypothalamic Obesity (N=35) Treated with Setmelanotide for up to Nine Months in French Early-access Program

      -- New data showed setmelanotide achieved consistent, meaningful weight reduction -- -- Multiple presentations delivered at the first-ever Joint Congress between the European Society for Paediatric Endocrinology and the European Society of Endocrinology (ESPE-ESE); 32nd annual European Congress on Obesity (ECO); and the 2025 annual meeting of the Pediatric Endocrine Society (PES 2025) -- BOSTON, May 14, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced the presentation of new, real-world data at two European congre

      5/14/25 8:00:00 AM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rhythm Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Update

      -- First quarter 2025 net product revenue from global sales of IMCIVREE® (setmelanotide) of $37.7 million -- -- Setmelanotide pivotal Phase 3 TRANSCEND trial met primary endpoint with -19.8% placebo-adjusted BMI reduction in patients (N=120) with acquired hypothalamic obesity -- -- U.S. and EU regulatory submissions for setmelanotide in acquired hypothalamic obesity on track to be completed in the third quarter of 2025 -- -- Topline data from Phase 2 trial of oral MC4R agonist bivamelagon on track to be announced in third quarter of 2025 -- -- Cash on-hand expected to support planned operations into 2027 -- -- Management to host conference call today at 8:00 a.m. ET -- B

      5/7/25 7:00:00 AM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences

      BOSTON, May 06, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that David Meeker, M.D., Chair, President and Chief Executive Officer, will participate in fireside chats at three upcoming investor conferences: Bank of America Securities 2025 Healthcare Conference on Wednesday, May 14, 2025 at 12:20 a.m. ETJefferies Global Healthcare Conference on Wednesday, June 4, 2025 at 3:10 p.m. ETGoldman Sachs Annual Healthcare Conference on Monday, June 9, 2025 at 8:00 a.m. ET The fireside chats will be webcasted and availab

      5/6/25 8:00:00 AM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care